Adolor Corp. lost almost half its value Tuesday after reporting results from three trials evaluating Entereg (alvimopan) for opioid-induced bowel dysfunction. Two of the trials failed to meet the primary endpoint, including one study designed to support a new drug application filing in the middle of 2007. (BioWorld Today)
Nearly four months after investors learned the FDA wanted more clinical data on Dyax Corp.'s hereditary angioedema drug DX-88, the agency recommended that the company complete a confirmatory Phase III trial to validate its patient reported outcome measure. (BioWorld Today)
